Scott M. Norberg, D.O.
Dr. Norberg researches the use of immunotherapy and cellular therapy for a variety of conditions including human papillomavirus-positive (HPV+) cancers and premalignant diseases caused by chronic HPV infection. His research focuses on understanding resistance to immunotherapy and cellular therapies and applying these treatment modalities to other conditions.
1) cell therapy, 2) immunotherapy, 3) human papillomavirus, 4) cervical cancer, 5) oropharyngeal cancer, 6) anal cancer
Dr. Norberg conducts clinical research to develop T cell therapies for the treatment of patients with cancer and precancerous diseases. This includes conducting clinical trials using genetically engineered T cells to treat patients with advanced human papillomavirus (HPV) malignancies.
Selected Recent Publications
- Curr Treat Options Oncol. 16(5): 24, 2015. [ Journal Article ]
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.Cancer Res. 66(3): 1434-45, 2006. [ Journal Article ]
- Am J Pathol. 167(1): 193-211, 2005. [ Journal Article ]
Dr. Norberg received his B.S. from Saint Mary’s College of California and a M.S. in Medical Sciences at Drexel University. He received his medical degree at the Philadelphia College of Osteopathic Medicine. He completed his residency in internal medicine at Temple University Hospital and a fellowship in medical oncology at the National Cancer Institute. After fellowship training, he joined the research group of Dr. Christian Hinrichs where he conducts clinical research to develop T-cell therapies for patients with malignant and premalignant disease.
Dr. Norberg is board certified in internal medicine and medical oncology.